NCT04733742View on ClinicalTrials.gov

Endovascular Treatment With Versus Without Intravenous rhTNK-tPA in Stroke

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

550

Participants

Timeline

Start Date

May 9, 2022

Primary Completion Date

December 16, 2024

Study Completion Date

February 7, 2025

Conditions
Stroke, AcuteStroke, Ischemic
Interventions
DRUG

rhTNK-tPA

intravenous thrombolysis with rhTNK-tPA followed by endovascular treatment

OTHER

Endovascular treatment

endovascular treatment

Trial Locations (6)

214000

The 904th Hospital of CPLA, Wuxi

400037

Xinqiao Hospital of Army Medical University, Chongqing

430000

Wuhan No. 1 Hospital, Wuhan

525000

Xiangtan Central Hospital, Xiangtan

Unknown

The Second Hospital of Jiaozuo, Jiaozuo

The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang

All Listed Sponsors
collaborator

CSPC RECOMGEN PHARMACEUTICAL (GUANGZHOU) CO.,LTD

UNKNOWN

lead

Xinqiao Hospital of Chongqing

OTHER